A review of the recent patent literature for bradykinin B2 receptor antagonists is presented for the period of 1994 to 1998. Although several very potent and selective peptide antagonists of bradykinin receptors are already known, the increasing number of recently disclosed patent applications claiming non-peptide B2 antagonists represents substantial progress towards further assessment of the role of bradykinin receptor antagonism in human pathophysiology.